

CLINICALBRIDGE

GBM gate coverage map

Before trusting the answer key, a check that every rule actually has patients that can test it. Each row is one distinct eligibility gate, the trials that impose it, and how many of the 25 validation patients pass, fail, or come out indeterminate. Computed directly from trial_gates.json and the cohort — not hand-entered.

Criterion	Trials	Pass	Fail	Indet.	Note
Age cap ≤ 100	T5	25	0	0	cohort ages 21–76; no case exceeds the cap, so it never fails
Age cap ≤ 80	T9, T20	25	0	0	cohort ages 21–76; no case exceeds the cap, so it never fails
Age cap ≤ 90	T12, T13, T23, T24	25	0	0	cohort ages 21–76; no case exceeds the cap, so it never fails
Age ≥ 18	T1, T2, T3, T4, T5, T6, T7, T8, T9, T10, T12, T13, T14, T15, T17, T19, T20, T21, T22, T23, T24, T25	25	0	0	every cohort case clears this rule
Age ≥ 19	T16	25	0	0	every cohort case clears this rule
Age ≥ 21	T18	25	0	0	every cohort case clears this rule
Age cap ≤ 75	T17	24	1	0	cleanly split — real true-positives and true-negatives
Age ≥ 22	T11	24	1	0	cleanly split — real true-positives and true-negatives
Age cap ≤ 70	T18	23	2	0	cleanly split — real true-positives and true-negatives
Diagnosis: GBM / HGG	T7, T12, T13, T16, T24, T25	25	0	0	every cohort case clears this rule
Diagnosis: GBM	T1, T2, T3, T4, T5, T6, T8, T9, T11, T14, T15, T17, T18, T19, T20, T21, T22, T23	23	2	0	cleanly split — real true-positives and true-negatives
Diagnosis: HGG	T10	2	23	0	cleanly split — real true-positives and true-negatives
Newly-diagnosed required	T1, T2, T13, T17, T19	13	12	0	cleanly split — real true-positives and true-negatives
Recurrent / progressive required	T3, T5, T6, T10, T14, T15, T16, T18, T20, T22, T23, T25	12	13	0	cleanly split — real true-positives and true-negatives
KPS ≥ 40	T16	23	1	1	
KPS ≥ 60	T1, T5, T10, T15, T18, T21	22	2	1	
KPS > 60	T2, T3	18	6	1	
KPS ≥ 70	T4, T6, T17, T19, T20, T22, T25	18	6	1	
KPS > 70	T9	14	10	1	

Criterion	Trials	Pass	Fail	Indet.	Note
≤ 2 prior therapy lines	T25	25	0	0	every cohort case clears this rule
No prior chemo/RT required	T5, T17	13	12	0	cleanly split — real true-positives and true-negatives
Prior RT + TMZ completed	T3, T10, T11, T15, T16, T20	12	13	0	cleanly split — real true-positives and true-negatives
IDH IDH-wildtype required	T17, T19	20	5	0	cleanly split — real true-positives and true-negatives
MGMT unmethylated required	T17	14	10	1	
IDH IDH-mutant required	T10	5	20	0	cleanly split — real true-positives and true-negatives
B7H3 positive (IHC)	T3	0	0	25	field not carried in the source cohorts — honest ground truth is indeterminate (not-assayed)
CD70 positive (IHC)	T9	0	0	25	field not carried in the source cohorts — honest ground truth is indeterminate (not-assayed)
GPC3 positive (IHC)	T18	0	0	25	field not carried in the source cohorts — honest ground truth is indeterminate (not-assayed)
Measurable disease (RANO)	T20	12	0	13	
Prior bevacizumab	T16	0	0	25	field not carried in the source cohorts — honest ground truth is indeterminate (not-assayed)
Willing to use TTFields	T11	0	0	25	field not carried in the source cohorts — honest ground truth is indeterminate (not-assayed)

“Indeterminate” means the fact needed to judge the rule isn’t in the source cohorts (for example RANO measurable disease or IHC biomarkers), so the honest ground truth is “not enough information.” An upper age cap shows all-pass because the cohort has no patient old enough to fail it — the rule is present but not exercised.